De Haro J - Search Results

1

C-reactive protein predicts aortic aneurysmal disease progression after endovascular repair.

De Haro J, Bleda S, Acin F. De Haro J, et al. Int J Cardiol. 2016 Jan 1;202:701-6. doi: 10.1016/j.ijcard.2015.09.122. Epub 2015 Oct 1. Int J Cardiol. 2016. PMID: 26454539

2

Relationship between the plasma concentration of C-reactive protein and severity of peripheral arterial disease.

De Haro J, Acin F, Medina FJ, Lopez-Quintana A, March JR. De Haro J, et al. Clin Med Cardiol. 2008 Dec 23;3:1-7. doi: 10.4137/cmc.s1062. Clin Med Cardiol. 2008. PMID: 20508761 Free PMC article.

3

Relationship between endothelial dependent vasodilation and size of abdominal aortic aneurysms.

Medina F, de Haro J, Florez A, Acin F. Medina F, et al. Among authors: de haro j. Ann Vasc Surg. 2010 Aug;24(6):752-7. doi: 10.1016/j.avsg.2009.11.011. Ann Vasc Surg. 2010. PMID: 20638617

4

Prediction of asymptomatic abdominal aortic aneurysm expansion by means of rate of variation of C-reactive protein plasma levels.

De Haro J, Acin F, Bleda S, Varela C, Medina FJ, Esparza L. De Haro J, et al. J Vasc Surg. 2012 Jul;56(1):45-52. doi: 10.1016/j.jvs.2012.01.003. Epub 2012 May 1. J Vasc Surg. 2012. PMID: 22551908 Free article.

5

Inflammatory burden predicts long-term outcomes in endovascular therapy in peripheral arterial disease.

Bleda S, De Haro J, Acin F, Varela C, Esparza L, López de Maturana I. Bleda S, et al. Among authors: de haro j. Ann Vasc Surg. 2013 May;27(4):459-66. doi: 10.1016/j.avsg.2012.02.027. Epub 2013 Feb 10. Ann Vasc Surg. 2013. PMID: 23403331

6

NLRP1 inflammasome, and not NLRP3, is the key in the shift to proinflammatory state on endothelial cells in peripheral arterial disease.

Bleda S, de Haro J, Varela C, Esparza L, Ferruelo A, Acin F. Bleda S, et al. Among authors: de haro j. Int J Cardiol. 2014 Mar 15;172(2):e282-4. doi: 10.1016/j.ijcard.2013.12.201. Epub 2014 Jan 9. Int J Cardiol. 2014. PMID: 24439873 No abstract available.

7

An open-label study on long-term outcomes of bosentan for treating ulcers in thromboangiitis obliterans (Buerger's disease).

De Haro J, Bleda S, Acin F. De Haro J, et al. Int J Cardiol. 2014 Dec 15;177(2):529-31. doi: 10.1016/j.ijcard.2014.08.107. Epub 2014 Aug 23. Int J Cardiol. 2014. PMID: 25217217 Clinical Trial. No abstract available.

8

C-reactive protein and endovascular treatment of lower limb peripheral artery disease: an independent prognostic factor.

Bleda S, de Haro J, Varela C, Acin F. Bleda S, et al. Among authors: de haro j. J Endovasc Ther. 2015 Apr;22(2):233-9. doi: 10.1177/1526602815573226. J Endovasc Ther. 2015. PMID: 25809368

9

The need for carefully reading. Time matters!

De Haro J, Bleda S, Acin F. De Haro J, et al. Int J Cardiol. 2016 Jan 15;203:1142-3. doi: 10.1016/j.ijcard.2015.11.120. Epub 2015 Nov 18. Int J Cardiol. 2016. PMID: 26614567 No abstract available.

10

Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients With Peripheral Arterial Disease.

De Haro J, Bleda S, Varela C, Esparza L, Acin F; Bosentan Population-Based Randomized Trial for Clinical and Endothelial Function Assessment on Endothelin Antagonist Therapy in Patients With Intermittent Claudication CLAU Investigators. De Haro J, et al. Am J Cardiol. 2016 Jan 15;117(2):295-301. doi: 10.1016/j.amjcard.2015.10.032. Epub 2015 Nov 6. Am J Cardiol. 2016. PMID: 26651453 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters